Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Insider Sale: 10% Owner at $BDTX Sells 2,000,000 Shares
Black Diamond Therapeutics(BDTX.US) 10% Shareholder Sells US$12 Million in Common Stock
Stifel Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $15
Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)
Trending Stocks Today | SAG Holdings Surges 60% Pre-Market
Sector Update: Health Care
Top Midday Gainers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Black Diamond Therapeutics Shares Surge on Servier Licensing Deal
Trending Stocks Today | Leishen Energy Surges 89.57% Pre-Market
Express News | Market-Moving News for March 19th
Black Diamond Therapeutics Shares Are Trading Higher After the Company Announced a Global Licensing Agreement With Servier for BDTX-4933.
Express News | Black Diamond Therapeutics - to Receive $70 Million Upfront, up to $710 Million in Milestones
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Black Diamond Theraptcs Price Target Raised to $12.00/Share From $11.00 by HC Wainwright & Co.
Black Diamond Theraptcs Is Maintained at Buy by Stifel
Black Diamond Therapeutic Analyst Ratings
Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating